STOCKS TELEGRAPH

Author: Ali Hassan

  • The 3 Best Pharmacy Stocks for long-term Investment

    The 3 Best Pharmacy Stocks for long-term Investment

    The pharma industry has been a long-term investment opportunity for investors over the years.

    The global pharmaceutical industry is a massive market that continues to grow each year. It is estimated to be more than $1.2 trillion in sales annually. The COVID-19 pandemic has been a massive catalyst in pushing pharma firms to their limit. The majority of the companies have tried their luck in developing the coronavirus vaccine—with several being successful and others under clinical trials.

    For investors, the pharmacy stocks have the potential to reap solid long-term results—with a broader market. Especially, with the demand for vaccines high all over the world, the pharma stocks could be making big profits in the future. So, let’s have a look at the three best pharma stocks for long-term investment.

    Pfizer (PFE)

    Pfizer (PFE) has been the highlight of last year. The US-based pharma firm was the first—in collaboration with BioNTech—to develop the COVID-19 vaccine. Despite the vaccine news, the stock price hasn’t skyrocketed as it was expected. So, there is much upside considering the stock being backed by Pfizer’s vaccine and other top-line products.

    Recently, the company reported its fourth-quarter results, with earnings on the lower side as per the expectations. The Q4 2020 adjusted earnings were $0.42 per share, topping by 14% Year-over-Year but missing analysts’ estimate of $0.51 per share. While, the sales increased by 12% to $11.68 billion, missing projected sales of $12.01 billion.

    Mizuho Securities analyst Vamil Divan said that the company has multiple parts under movement, but the long-term seems strong with its core assets performing well. Pfizer has reportedly said that they are expecting $15 billion of vaccine sales this year. So far, the company has vaccine sales of around $154 million.

    With much happening, Pfizer (PFE) stock is still in the buy range.

    Bristol-Myers (BMY)

    Bristol Myers Squibb (BMY) is one of the leading pharmaceutical firms in biologics in several therapeutic areas, including cancer. The company is set to release its fourth-quarter results on Feb. 4, 2021.

    According to Forbes, the overall outcome is expected to be slightly on the lighter side as per the analysts’ estimate. The quarterly results are affected by a slow sales growth rate of Opdivo. However, the company should see an increase in overall demand due to a rise in hospital visits.

    The company has announced that it has obtained positive outcomes from the second pivotal Phase 3 trial for its novel, oral, POETYK PSO-2. Bristol is working on selective tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis—patients with moderate to severe disease. Almost 100 million people are suffering from psoriasis around the world. If the company goes on to successfully market its product, it would bring massive revenue in the longer run.

    Furthermore, Bristol Myers Squibb (BMY) has collaborated with The Rockefeller University for the rights to a Covid-19 therapy that combines two antibodies. The company stated that the vaccine variant of Rockefeller has delivered effective results against SARS-CoV-2. So, this deal could be another big plus for Bristol as we head forward.

    Anavex (AVXL)

    Anavex Life Sciences (AVXL) is a promising biopharma firm that has gained a lot of attention for its lead candidate of Alzheimer’s disease, Anavex 2-73 (A2-73). Recently, the company updated that it has completed 80enrollment for the Phase 2b/3 trials. While the remaining enrollment of 450 patients is anticipated in near-future.

    Over the past 12-months, AVXL shares have soared over 163%. As of Feb. 4, in pre-market trading, the stock is up by nearly 87% trading around $19.67. The bullish sentiment is pushed by the lead drug of Anavex.

    So far, the data shows that Anavex 2-73 is very effective against Alzheimer’s disease. According to World Health Organization, more than 50 million suffer from dementia—a type of Alzheimer—all over the world. And, around 10 million new cases arise each year.

    Being bullish on Anavex, Seeking Alpha’scontributor Lane Simonian stated that Anavex 2-73 has the best chance of long-term success among the rest of the drugs being studied by the company. So, Anavex (AVXL) is a stock to watch for long-term investment.

  • Ryman Hospitality (RHP) Rebooking activity continues to grow; has much upside potential

    Ryman Hospitality (RHP) Rebooking activity continues to grow; has much upside potential

    After falling short to the bookings in 2020, Ryman’s bounces back with rebooking incline in Q4.

    Ryman Hospitality Properties (RHP) is a hotel, resort, entertainment, and media company. RHP stock has soared significantly since November 2020. Post pandemic RHP stock was doing great and the company was making a good amount of profit. The pandemic has hit hard on Ryman’s operations with lockdowns and other restrictions.

    However, in the recent quarterly outlook, the company has reported promising results—with an increase in rebooking.

    What’s Next?

    Earlier in Jan. 2021, the company scheduled to release its fourth-quarter earnings results on Feb. 26. Additionally, Ryman has presented an initial outlook of the Q4 outcomes.

    The pandemic has massively affected the hospitality industry. Ryman reported that a cumulative 2.4 million group room nights were canceled between March 2020 and Jan. 21, 2021.

    In the Q4 outlook, the company has highlighted that its rebooking activity continues to grow. Around 58% of the canceled bookings have been rebooked for future periods, exceeding the firm’s target of 50%. Whereas, there the cancellations in Q3 and Q4 were quite modest.

    Ryman’s hospitability portfolio was profitable with almost 19.6% occupancy during the fourth quarter. Moreover, the company ran successful programs during the holiday periods which attracter customers and around 1 million event tickets were sold in Q4.

    As of year-end 2020, the group occupancy for the second half of this year is at reasonable levels—not much below from the prior year. The Gaylord Texan hosted a survey asking meeting attendees from Meeting Planners International (MPI) for their opinion regarding the COVID-19 outlook. More than 75% of respondents replied that if the vaccine is deployed at a broader level during the first quarter of 2021 then the company could be in a position to resume in-person meetings before Q4 2021. 

    The company posted Survey’s stats in the Q4 outlook, which shows that Ryman management is quite optimistic that they would resume full business activities by the end of this year.

    However, the Q4 guidance is subject to risks and uncertainties that could change the actual outcomes of the quarter.

    Conclusion

    Ryman Hospitality Properties (RHP) has shown positive outcomes, still, there is much risk as the vaccine isn’t available to the masses. But, with risk, there is massive upside potential for RHP stock. The investors should keenly examine the upcoming outcomes and what the company plans for this year. For now, Ryman stock is a hold.

  • Mmtec (MTC): The Penny stock that Traders fancy

    Mmtec (MTC): The Penny stock that Traders fancy

    The Chinese internet-based tech firm has been on traders’ radar recently, making significant movements.

    Mmtec, Inc. (MTC) shares have been on a bumpy ride as the traders seem to enjoy making profits out of the stock. MTC stock has been trading on the higher side in the past few months. Mmtec made some notable movements in the past month soaring as high as $2.60.

    With no news in the market, Mmtec continues to be a favorite bet for traders—as the average volume is just below 3.5 million. It has been more than half a year when the company updated with its first six months outcomes of 2020.

    What’s Next?

    Mmtec, Inc. (MTC) is a Chinese-based firm that provides online trading services. The company offers digital-tech services and solutions in securities market transactions. The consumers of the company are from financial backgrounds including investment advisors, brokerage firms, and proprietary trading groups—all over the world.

    Mmtec shares surged from under the $1 per share in early November last year and have traded in the $1 and $2.5 range—in the meantime. While over the past 12-months period the stock has traded between $0.6400 – $7.700.

    In December, Mmtec shares surged over 50%, whereas since September the stock has rallied up to 200%. The major reason why investors are driven towards the financial services platform is Mmtec’splacement in the online tech services and solutions market.

    The renowned Chinese financial firms that use its solutions include ETN Counter Business System, Personal Mobile Transaction Client System, PTN Private Mutual Fund Investment Management System, and others.

    The company went public on the US stock in Jan. 2019. So, it’s fairly new—to the surprise, it’s one of the highly traded stocks in the market, today. This shows that investors are pretty optimistic as we head forward.

    All this bullish sentiment is based on the first half reports that the company published back in 2020. With high expectations, the company reported promising outcomes that attracted investors—playing an integral part in the shares price jump, in September. Mmtec reported revenue of $329,070, approximately up by 85%. While the cost of revenue dropped by more than 80%.

    The company was successful in lowering its operational losses by 30% to $1.04 million in the first half of 2020. That was a big boost amid the pandemic crisis.

    Conclusion

    Mmtec, Inc. (MTC) believes that Chinese investors would be keener to adapt its services for investing in US-based assets. At the mid-year 2020, the company was assuming good US-China relations, predicating Joe Biden to grab the Presidential position. Since then, the assumptions have come true and the US-China trade war seems to ease off. In recent days, there has been much happening in the US market—the GameStop show. So, we need to hear from the company as it updates on the full-year results.

  • The 3 Top Ammunition Stocks to Buy with Rising Demand

    The 3 Top Ammunition Stocks to Buy with Rising Demand

    The demand for Ammunition such as guns is on a rise since the murder of African-American George Floyd.

    2020 has been an extraordinary year, full of surprises and uncertainties. The COVID-19 pandemic wasn’t enough as the killing of 46 years African-American George Floyd took place on May 25, 2020. Since then, there has been civil unrest in the US. On top of that, about a month ago, Trump enthusiast marched outside the White House protesting against the unfair elections.

    During this period of agitation, the demand for ammunition increased and the sales for guns were on a rise. As a result, U.S.-listed gun and ammunition stocks outperformed the broader market. The demand has continued since and the ammunition stocks have rallied over time. Here are the three top ammunition stocks to buy this year.

    Smith & Wesson Brands (SWBI)

    Smith & Wesson Brands (SWBI) is one of the most renowned names in the ammunition industry. Since dropping to the lows of $4.42 in March last year, SWBI shares have skyrocketed to a high of $23.57 in January 2021.

    With the recent pullback to $16.77, as of Feb. 2, SWBI stock has an upside amid the high demand for guns in the market. The demand for guns spiked during the second quarter last year, with sales more than doubled year-over-year. In Q4 2020, the company reported consumer demand for firearms increased dramatically. The revenue was up by 37% YoY to $193 million.

    The growing demand keeps the analyst on the bullish side. Wall Street is quite optimistic as SWBI approaches its next earnings report date. According to Street, the company is projected to report earnings of $0.82, a whopping growth of 530.77% YoY. While the Zacks predict the net sales to top $264.70 million, almost a 58.80% increase from the prior-year period.

    AMMO (POWW)

    Ammo (POWW) is an emerging ammunition company that has had an astonishing period recently. The company with a small market cap of 331.783 million is growing well. The rising demand for ammunition in the US has helped the stock price touch its all-time high earlier this year.

    The company has provided its fourth-quarter outlook, which reflects phenomenal revenue growth of 317% YoY. This would be the fourth consecutive quarter with triple-digit growth year-over-year—for Ammo.

    As we head forward, the company anticipates ammunition demand to increase further. Based on the recent US senate election, Ammo believes that the demand for ammunition would continue to spike amid the political uncertainty. So, it’s a promising ammunition stock to buy this year.

    Olin Corp. (OLN)

    Olin Corp. (OLN) is a chemical industry stalwart but it plays a major role in the firearms industry. As an investor, you would not want to roll out OLN stock for a potential investment option this year.

    Olin shares are once again popping up signaling to cross the 52-week high. The company recently posted the Q4 results which were decent considering the pandemic. Olin’s revenue soared over 19% to $1,654.1 million during the quarter; surpassing the consensus estimate of $1,460.6 million.

    The Zacks consensus estimate for this year’s earnings has increased more than 100% over the last 60 days. However, in the recent quarter, Olin posted a loss of $0.21 compared to $0.49 in the same period last year.

    However, the current consensus shows that due to the higher demand for ammunition and better business circumstances than earlier 2020, Olin has more upside. So, keep Olin Corp. (OLN) in your books.

  • Could Titan International (TWI) Stock aim for the $8 Per Share ‎mark?

    Titan has been on the bullish side since August 2020. What’s the analyst sentiment that could potentially help TWI in the long-term? Let’s have a look.

    Titan International (TWI) shares have pumped higher in rent months. TWI more than doubled in the last year and is up by 35% already so far in 2021. The company seems to push as the demand for agriculture products has recently spiked in the country.

    The company has recovered its debts to some extent and had increased its cash balance by the end of the third quarter. So, what’s the prospect for Titan as we move into 2021.

    What’s Next?

    Titan International (TWI) is a global manufacturer and distributor of wheel systems for off-highway equipment that are used in agriculture, mining, construction, and other fields. The rally in TWI could be due to certain factors.

    The fact that the North American harvest season has resulted in remarkable outcomes—especially the increase in corn and soybeans. Due to growth in the agriculture segment, farmers have earned more to upgrade their equipment.

    The company has three major businesses from which it generates revenues. As per 2019 stats, Titan had 45% sales from agriculture, 45% from mining/earthmoving/construction, and 10% from the consumer.

    The company in its Q3 2020 transcript noted that the farmers’ sentiment is high as they near a 5-year high. Moreover, there have been notable improvements in the dealer engagement—with 30% of AG dealers reporting low current inventory levels. So, the company believes that there is a good momentum that could kick-start the replacement cycle.

    Furthermore, if the Biden government takes some prominent steps that could sustain the China-US trade relations, we could see farmers being more optimistic about the future—which can potentially lead to more equipment buying.

    In the third quarter of 2020, the company ended the three months with a cash balance of $98.8 million, up by $18.6 million during Q3. While the net debt was lowered up to $85 million in the last 12 months, as of Q3. The company’s debt was at its lowest since Q3 2018, which is much needed—to keep the balance—in the pandemic period.

    Conclusion

    Titan International (TWI)is trading in the range of $7.14 – $7.65, as we write this. The company has much room for improvement in its sales. And, if the demand for its products really speeds up, we could see TWI stock popping higher—probably touching $8 per share.

  • The 3 Best Home Improvement Stocks to buy in 2021

    The 3 Best Home Improvement Stocks to buy in 2021

    The best home improvement stocks in the market to watch for in 2021.

    While staying at home all the time, people have had a new hobby; how to renovate or upgrade their homes. With nothing much to do, there has been a surge of interest among consumers in home improvement projects.

    Home improvement seems to have become a priority for consumers. That’s the reason why the home improvement firms were one of the biggest gainers during the pandemic. But what would happen once the pandemic ends?

    Let’s have a look at the three best home improvement stocks that have a strong long-term prospect.

    Home Depot (HD)

    Home Depot (HD) is one of the biggest home improvement enterprise in the market, with over 2,200 Home Depot stores across the U.S., Canada, and Mexico. HD stock made thriving progress in the past year—thanks to the increase in sales.

    During the pandemic period last year, the company added more than $15 billion to its sales base and made sky-touching profits during the first nine months of 2020. The outlook for Home Depot is bright as we head forward. While vaccine development is still underway there is a way to go before things could turn to normal. So, there is still substantial for home improvement to maintain sequential growth.

    Moreover, Home Depot’s fundamental track record is quite astonishing. The company’s EPS has soared up to 4% from $2.03 in 2011 to $10.25 in 2020. The double-digit growth shows that Home Depot’s demand has surged massively and should lift the business well enough in 2021.

    Wall Street anticipates Home Depot’s (HD) earnings to jump 15% in FY21 up to $11.83 per share. So, Home Depot is the big fish in the home improvement segment—for investment this year.

    Wayfair (W)

    Wayfair (W) is one of the world’s leading online destination for the home. The significance of Wayfair has grown with the pandemic and the evolution of the digital world. The company is well-established and its business model makes it a long-term stock.

    In the third quarter of 2020, the company reported net revenue of $3.8 billion, popping up to 66.5% year-over-year. While the US net revenue soared $1.3 billion, also up by 66.5% YoY. The global net revenues jumped $225.9 million, with a 66.7% growth. And, the gross profit was around $1.1 billion.

    The company is set to release the Q4 and full-year 2020 results on Feb. 25, 2021. The quarterly results are expected to report high revenue to due more demand for renovations in the holiday season.

    The CEO of Niraj Shah stated that their long-term goal and strategic investments in merchandising, selection, service, and delivery across North America and Europe would continue sustained profitability. This would help in positive free cash flow generation in the coming quarters. So, with long-term plans, Mayfair (W) is set to grow its market value—ultimately pushing the stock price.

    Builders FirstSource (BLDR)

    Builders FirstSource (BLDR) is a Dallas-based Fortune 500 company that manufactures and supplies building materials. The company has been doing great in the recent past—driven by the pandemic boost.

    BLDR stock has made notable growth since the lockdown period, soaring from $10.91 on March 30, 2020, to $43.48 on Jan. 18, 2021. BLDR shares closed the session on Feb. 1 at $39.42.

    Based on the firm’s continuous earnings consensus beat, Zacks expect the company to cross earnings estimate in yet another quarter. Builders FirstSource has scheduled to release the Q4 and full-year 2020 results on Feb. 26. The construction supply company has seen a continuous beat in earnings estimate—popping up by an average surprise of 89.15% in the past two quarters.

    In Q3 2020, the company reported net sales of $2.3 billion, up by almost 15.9% YoY. While the basic organic sales soared over 6.7%. The accusations—which the company made in the past year—accounted for a total contribution of 2% in net sales. The gross margin increased up to $29.5 million, totaling $570.7 million during the quarter.

    As per Zacks, the company has an Earnings ESP of +1.93%, as of now. This shows that the analysts have a bullish sentiment on the construction supply firm. Builders FirstSource (BLDR) is making good progress and is set to make good moves this year.

  • LTC Properties (LTC) Stock Soars as it nears the fourth quarter earnings release

    LTC Properties (LTC) Stock Soars as it nears the fourth quarter earnings release

    LTC has lagged during the pandemic but with much promise, the stock showed resistance throughout the period.

    As LTC Properties (LTC) nears the earnings release, the shares are starting to pump—aiming for $40 per share. Currently, LTC stock is trading at $39.29 up by 1.68%.

    While the average trading volume of LTC is just under 250K, which means that investors are happy to jump in trading the dividend-based stock. The company has just announced its fourth-quarter results to be released soon, so what’s coming up?

    What’s Next?

    LTC Properties (LTC) is a US-based real estate investment trust (REIT) that invests in senior housing and health care properties. LTC is a conservatively levered REIT that maintains a comfortable dividend payout, which is paid from cash flows rather than EPS.

    The pandemic harmed LTC’s operations, but now with vaccine availability, things are expected to change in the next few months. During the past year, the company maintained fairly comparable FAD, with the drop partially related to lower rents received from Senior Lifestyle.

    The CEO of LTC in the Q3 report highlighted that they have recorded continued support from the government. Moreover, they received higher rent from its Senior Lifestyle portfolio compared to prior quarters.

    With things getting better now, the company will continue to support its operators. The company has also announced to reduce its rent escalation by 50% in 2021. This escalation will be in the form of a rent credit, providing financial support to its operating partners during these tough times.

    This one-time rent escalation reduction would probably have a $560K impact on LTC’s GAAP revenue for Q1 2021. While the funds available for distribution (FAD) would be around $1.4 million. This would create a good reliable relationship between the company and the operators in this crisis. The company wants to support its operators in any manner it can, continuing business operations and maintain cooperation with operators.

    Furthermore, LTC has scheduled the fourth quarter 2020 earnings results set to release on Feb. 18, 2021. The next day, the company will hold a conference call to discuss the quarterly outcomes with analysts and investors.

    The company has also declared the quarterly dividends that are to be payable on March 31 to its shareholders. LTC has announced a dividend payout of $0.19 for each common stock share, which equals a dividend yield of 5.90% at recent price levels.

    Conclusion

    LTC Properties (LTC) is trying to cope up with the pandemic situation quite well. As the Q4 earnings release nears, the stock would pop up and down. According to Zacks, in Q1 2021, LTC is expected to report an EPS of $0.71 per share from $0.81 per share year-over-year.

  • BioXcel Therapeutics (BTAI) is a hot investment option; Here is what you should know

    BioXcel Therapeutics (BTAI) is a hot investment option; Here is what you should know

    BioXcel is going big—with notable developments—that could push the stock higher than its 52-week high of $71.50, in the coming months.

    BioXcel Therapeutics (BTAI) is making way into a newly evolving industry in the health sciences—biotech. BTAI had a superb last year with notable developments. The popularity of the company is due to its use of artificial intelligence in drug discovery.

    As we write this on Feb. 1, BTAI shares were soaring by 8.96% trading around $50.47.In the past year, when the rest of the stock market was dropping—in March—BioXcel entered the bullish momentum. Initially, the business was paused due to the pandemic restrictions, however, the biotech company kept on performing well.

    What’s Next?

    BioXcelTherapeutics (BTAI) grew its revenue to over20% in the fiscal year 2020. So, the sales were decent enough to push the revenues. For this year, the company projects to maintain organic growth of 15%-20%, with additional acquisitions possibly pushing the overall growth even further.

    BioXcel stands out for its development in AI-based solutions and drug discovery. The biotech firm is incorporating the power of next-generation technology. Through this BioXcel would have a swifter growth and transformation would be phenomenal due to smart tech. This opens up a lot of opportunities for BioXcel to thrive in different segments and diversify its portfolio.

    At the moment, the most significant project of BioXcel is its proprietary, orally dissolving thin film formulation of dexmedetomidine, BXCL501. This topline drug is being developed for the acute treatment of agitation in dementia patients, including those with Alzheimer’s disease.

    Recently, the company announced the topline results from the Phase 1b/2 TRANQUILITY trial of BXCL501. The results from the trials were statistically significant and clinically meaningful. Moreover, BXCL501 showed fast and durable reductions in agitation that was obtained with the 60 mg dose.

    The CEO of BioXcel stated the current analysis shows that BXCL501 has a massive potential to treat the full spectrum of agitation in patients with dementia. The company plans to take the drug trials into a late-stage study later this year, following that dialogue with the FDA.

    It is estimated that around 4 million people in the US are suffering from agitation associated with dementia affects. If BXCL501 achieves all the end-points of the study following the approval from the FDA, it would change things for the patients. Also, this would ultimately bring tons of revenue for the company.

    Conclusion

    BioXcelTherapeutics (BTAI) is still growing with astonishing potential alongside—AI tech is a massive gateway to success. The biotech industry has a wide range and various opportunities to embrace its place in the health market. For investors; with continued growth expected this year, BTAI is a stock to go with.

  • The Top 3 Consumer Staples Stocks to Watch For in 2021

    The Top 3 Consumer Staples Stocks to Watch For in 2021

    The environment is challenging but there are some consumer staple firms with an upper hand in the market.

    The consumer staples firms are the basic necessity product makers or more likely which consumers use on daily basis. Though pandemic has impacted consumer staples companies, you rely on their products every single day.

    Consumer staples include daily life essentials such as food and beverages, cosmetics, cleaning, and personal hygiene products, tobacco, alcohol, and other daily use items. In the later period of 2020, the stock market made a promising recovery—reflecting a better and retrieval time for companies, this year.

    There are some well-positioned stocks in the market regardless of the unprecedented economic conditions. Moreover, the Biden government is expected to make changes that will take some burden off the economy. So, let’s have a look at consumer staples stocks to watch for in 2021.

    Procter & Gamble (PG)

    Procter & Gamble (PG) is one of the most decorated multinational consumer goods corporations. In tough COVID circumstances, the company kept on running its business with smoothness.

    In the recent earnings report, the CFO of Jon Moeller highlighted that they continued the strong momentum in Q4 2020, which PG has created over the past few years—top line, bottom line, and cash. The company reported strong sales, increasing profit, and cash flow.

    P&G kept up the good results despite the slowing of the demand from the lockdowns. The organic sales soared over 12% year-over-year in the US. The company ended the quarter on a high note, mainly due to the rising demand for home cleaning and maintenance products.

    Furthermore, Procter & Gamble (PG) stock has a big edge, with its dividend delivery. The company will issue a $0.79 per share quarterly dividend in Feb., making it’s the 131st consecutive year of paying dividends in 2021.

    Altria Group (MO)

    After a bumpy ride in 2020, Altria (MO) is well-positioned to have a decent run in 2020. Thanks to its strategic investments in key growth markets. Altria is a tobacco company that is behind some of the famous brands including Marlboro cigarettes, Black & Mild cigars, Copenhagen, and Skoal chewing tobacco.

    Recently, the company posted promising Q4 results—stronger quarterly sales. The quarterly net revenues soared 4.9% year-on-year to $6.3 billion, surpassing analysts’ estimates of $5 billion. While the revenues for the full-year 2020 jumped by 4.2% to $26.1 billion.

    Whereas, the full-year earnings grew to $2.40 per share. Upon the recent earnings report, analysts have given the forecast for the fiscal year 2021. The company is projected to record revenues up to $21.2 billion, while the statutory earnings per share are forecasted to jump 91% to $4.59. So, Altria Group (MO) is well-established to continue a strong quarterly performance this year—ultimately driving the stock.

    Clorox (CLX)

    The Clorox Company (CLX) is the US-based producer and marker of consumer products. Recently, CLX stock has been on the downward side, but it has rallied well in the last year amid the pandemic crisis.

    The company is scheduled to report its Q2 FY21 outcomes on February 4. Clorox expects strong growth and an increase in revenue and earnings in Q2. As per the Zacks Consensus estimate, the consumer product manufacturer is set to touch earnings of $1.69 per share. This will be almost a 15.8% rise from a year ago. While the revenues are anticipated to grow by 21.8% year-over-year to $1.76 billion.

    So, The Clorox Company (CLX) is set to pump is the earnings report gains the investors’ attention. Overall, CLX stock has a long-term potential with strong quarterly performances during the past year.

  • Masimo Corp. (MASI) Shares are down Despite Promising Preliminary 2020 Results

    Masimo Corp. (MASI) Shares are down Despite Promising Preliminary 2020 Results

    Masimo has shown promising growth during 2020 despite the serious pandemic hit.

    Shares of the American manufacturer of non-invasive patient monitoring technologies, Masimo Corp. (MASI) are going down, as we write this on Friday. So far, MASI has plunged over 1.42% to $253.90. Masimo shares have dipped from $283.75 on Jan. 8 to as low as $251 on Jan. 27.

    After a healthy bullish run from the past six months, MASI seems to cover up and aims for the recovery point. However, Masimo has enough bulls to push the stock up again in the long-term. This may be a good time as the stock drops and creates an entry point for experienced investors.

    What’s Happening?

    The company will discuss the complete fourth quarter and full-year 2020 financial results after the closing of the market on Feb. 23, 2021. Though it has released preliminary results for the past year, which are quite encouraging.

    The full-year 2020 revenues are anticipated between $1.139 billion and $1.144 billion, which means a forecasted growth of 21.6% to 22.2%. The company expects the total non-invasive technology board shipments to be around 472K during last year. While the GAAP and non-GAAP earnings per diluted share are predicted to cross financial guidance of $3.77 and $3.46 per diluted share, respectively.

    Masimo Corp. (MASI) also updated the full-year 2021 outlook in the preliminary results of last year. The revenue for 2021 is forecasted to cross $1.2 billion, which would be almost 5% higher than 2020’s expected revenue. So, the company is on the right track and the potential growth of earnings per share and revenues would support the stock in the long-term.

    On the business side, the company recently announced the global launch of its iSirona™. Masimo’s compact and versatile connectivity hub, iSirona, is developed to increase interoperability across the continuum of care. iSirona would help in storing offline data online giving a smooth data flow, ultimately, helping clinicians improve patient care.

    For investor’s note, Masimo’s latest Hospital Automation platform is a future-focused connectivity solution that would secure data flow and ensure interoperability in hospital systems. Thus, this new addition will diversity the product line of Masimo and accelerate the revenue growth in the years to come.

    Conclusion

    Though Masimo Corp.’s stock might continue to plunge in the near-term, the long-term prospects are rock solid. The company would attract more demand for its new connectivity hub in the coming years. The future outlook is also positive that would drive the stock as we head forward.